- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS
Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Johannes Schetelig, MD, director of medical research at DKMS; as well as a professor at Technical University Dresden, discussed findings from the phase 2/3 HAMLET trial (NCT03275636) comparing survival outcomes with haploidentical related and single human leukocyte antigen loci–mismatched unrelated donor transplantation in patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome.
Related Content:
